Additionally, there is emerging pre-clinical and clinical data explaining potential mechanisms by which CDKN2A deletions, perhaps in combination with other concurrent genetic aberrations, contribute to tumor progression in pediatric LGGs. The gene discussed is CDKN2A; the disease is neoplasm.